Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she has taken to support research and development of the ACI-24 Alzheimer’s disease treatment.
The Department funds research through the National Institute for Health and Care Research (NIHR). The Government is strongly committed to supporting research into dementia, including Alzheimer’s disease treatment, and has committed to doubling funding for dementia research to £160 million per year, by the end of 2024/25.
In addition, the NIHR’s infrastructure provides funding for clinical expertise, specialist facilities, the workforce, and support services, which underpin research across a range of clinical areas, including Alzheimer’s disease treatments. Specifically, the NIHR’s Oxford Health Clinical Research Facility (CRF) has enabled the delivery of the ABATE part 1 trial, which seeks to study the effects of the ACI-24 vaccine in those diagnosed with early-stage Alzheimer’s disease. The NIHR’s CRFs are purpose-built facilities for early-phase, experimental medicine, and supporting life science companies throughout the research process from study, design, data collection, and trial management.